

# Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

## Recombinant Anti-MelanA antibody [EPR20380]

RRID:AB\_2889292

Type: Antibody

---

### Proper Citation

Abcam Cat# ab210546, RRID:AB\_2889292

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2889292](http://antibodyregistry.org/AB_2889292)

**Proper Citation:** Abcam Cat# ab210546, RRID:AB\_2889292

**Target Antigen:** MelanA

**Clonality:** recombinant monoclonal

**Antibody Name:** Recombinant Anti-MelanA antibody [EPR20380]

**Description:** This recombinant monoclonal targets MelanA

**Clone ID:** EPR20380

**Antibody ID:** AB\_2889292

**Vendor:** Abcam

**Catalog Number:** ab210546

**Record Creation Time:** 20231110T031708+0000

**Record Last Update:** 20260829T043244+0000

---

### Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-MelanA antibody [EPR20380].

No alerts have been found for Recombinant Anti-MelanA antibody [EPR20380].

---

### Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Raymundo JR, et al. (2026) KCTD1/KCTD15 complexes repress AP-2? and AP-2? to regulate neural crest-dependent craniofacial morphogenesis and scalp skin development. The Journal of investigative dermatology.

Xu X, et al. (2026) A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma. Cancer research, 86(15), 3666.

Lucotti S, et al. (2025) Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell, 188(6), 1642.

Srour N, et al. (2022) PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. Cell reports, 38(13), 110582.

Choi YS, et al. (2022) Topical therapy for regression and melanoma prevention of congenital giant nevi. Cell, 185(12), 2071.

Rosenbaum SR, et al. (2021) SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell reports, 37(10), 110085.